Home » News » CROs/Service Providers » Venn Life Sciences acquires Medevol

Venn Life Sciences acquires Medevol

Wednesday, December 11, 2013

European CRO Venn Life Sciences has acquired Medevol, a CRO based in Northern Ireland, for a total maximum consideration of $1.1 million.

Venn has acquired the entire issued share capital of Medevol for an initial cash consideration of $1.15 million. There will be additional deferred consideration payable of up to a maximum of $1 million over the next two years should Medevol hit certain financial targets relating to the business’s annualized profit before tax.  Any additional consideration will be satisfied as to one half in cash and one half in Venn shares.

The acquisition of Belfast-based Medevol further strengthens Venn’s U.K. operations following the establishment of a U.K. office earlier in 2013.

Tony Richardson, CEO of Venn, said, “Medevol is the right fit for Venn, as we continue to expand our business across Europe and increase our project pipeline. Venn, Medevol and the CRM business (acquired from CRM Clinical Trials) have a shared global pharmaceutical client, and this acquisition affords us the opportunity to develop that relationship as a key strategic account for the group going forward.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!